<DOC>
	<DOC>NCT01720485</DOC>
	<brief_summary>The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis in Adults.</brief_summary>
	<brief_title>Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Dexchlorpheniramine</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Signed Consent of the patient; Clinical diagnosis of moderate severe persistent allergic rhinitis according to ARIA classification(Allergic Rhinitis and Its Impact on Asthma); Adults aged â‰¥ 18 years old; Evidence of sensitization to aeroallergens in examination (immediate skin tests or serum specific IgE) in the 12 months prior to inclusion. Decongestants dependent patients or patients receiving allergen specific immunotherapy; Patients who were in use of oral antihistamines or decongestants in the past 15 days; Patients who were treated with systemic corticosteroids in the last month; Patients on treatment with monoamine oxidase inhibitors (MAOIs); Patients with history of hypersensitivity to any of the formula compounds; Patients with any clinically significant disease that in the investigator opinion can not participate in the study Patients who have uncontrolled asthma, chronic sinusitis, drug related rhinitis and nasal anatomic abnormalities. Participation in clinical trial in 30 days prior to study entry;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>